Liu Z-F et al. – A modified FOLFOX-4 regimen (biweekly oxaliplatin [OXA] with continuous infusional 5-fluorouracil [5-FU] and leucovorin [LV] every 2 wks) is active and well-tolerated in elderly pts with advanced gastric cancer (AGC); OXA may cause mild hypersensitivity Methods
Study of toxicity and clinical activity of modified FOLFOX-4 regimen in 44 previously untreated AGC pts age ≥ 65
Administration of OXA 85 mg m-2 on day 1, LV 200 mg m-2 as 2-hr infusion followed by a 22-hr infusion of 5-FU 1000 mg m-2, repeated for 2 consecutive days every 2 wks
Results
All pts assessable for toxicity and 40 pts for response; median age 69 yrs
Response rate by RECIST criteria: 52.5%: 3 complete responses, 18 partial responses, 11 stable diseases, and 8 progressions
Median time to progression: 6.5 mo; median overall survival: 10 mo
See all
